Form 4: Marinus Pharmaceuticals Officer Shafer Christina Reports Disposition of Shares and Stock Options Following Merger Agreement

Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, reports the disposition of common stock and stock options following the merger agreement with Immedica Pharma AB.

Summary

• Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the disposition of common stock and stock options due to the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB.
• Shafer disposed of 18,778 shares of common stock at $0.55 per share on February 7, 2025.
• An additional 48,628 shares underlying Restricted Stock Units (RSUs) were terminated for a cash payment of $0.55 per share on February 11, 2025.
• Out-of-the-money stock options were terminated without payment, including options to buy 49,125 shares at $1.40, 98,250 shares at $9.74, 78,188 shares at $5.94, 57,900 shares at $10.40, 15,000 shares at $12.60, and 128,000 shares at $13.71.
• The transactions are a result of the merger agreement where Marinus Pharmaceuticals will be acquired by Immedica Pharma AB for $0.55 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions related to a merger agreement. There are no explicit positive or negative statements about the company's performance, only the reporting of required information.

Negatives

• The reporting person's stock options were terminated without payment as they were out-of-the-money, meaning the exercise price was higher than the merger price of $0.55 per share.

Future Outlook

The future outlook is centered around the completion of the merger agreement with Immedica Pharma AB.

Industry Context

This announcement reflects a trend of pharmaceutical companies undergoing mergers and acquisitions to consolidate resources and expand market reach. The acquisition of Marinus Pharmaceuticals by Immedica Pharma AB is indicative of this trend.

Comparison to Industry Standards

• Comparing this acquisition to other pharmaceutical mergers, the price per share is relatively low, suggesting Marinus may have been undervalued or facing financial difficulties.
• Similar deals in the pharmaceutical sector often involve higher premiums, especially for companies with promising drug candidates or established market presence.
• For example, acquisitions of companies with approved drugs typically command higher valuations than those with only pipeline assets.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees may experience changes as a result of the merger with Immedica Pharma AB.

Key Dates

Keywords

Form 4, Marinus Pharmaceuticals, MRNS, Shafer Christina, Immedica Pharma AB, Merger Agreement, Disposition, Stock Options, Restricted Stock Units, Beneficial Ownership